🇺🇸 FDA
Pipeline program

Moxonidine 0.2 MG

REG 15-021

Approved small_molecule completed

Quick answer

Moxonidine 0.2 MG for Central Sympathetic Nervous System Diseases is a Approved program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).

Program details

Company
Hospital Authority, Hong Kong
Indication
Central Sympathetic Nervous System Diseases
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials